JSR Corporation has acquired Crown Bioscience for more than $405m – the company’s largest investment to date as it turns its attention towards preclinical support for biopharma, says Life Sciences president.
Only eight of the top 40 CROs are Privacy Shield Framework-certified, says Science Exchange CEO as the company continues to rack up partnerships with pharma companies looking to streamline outsourcing efforts and mitigate risk.
Lonza has agreed to buy US capsule manufacturer Capsugel for $5.5bn (€5.2bn) in cash in an acquisition the Swiss firm says will expand its drug delivery business and enable savings of CHF100m a year by 2019.
With more than 90% of revenue coming from pharma and biotech companies outside the top 25, CRO SynteractHCR is seeing more growth stemming from an influx of funding to smaller biotech companies, CEO Wendel Barr told us on the third day of the 51st annual...
Chicago-based Rottendorf Pharmaceuticals, a top 20 contract development and manufacturing organization (CDMO), has signed three formulation development projects and two commercial transfer projects with multiple top pharma and biotech companies in the...
Parexel’s future course may depend on the outlook of competing CROs (contract research organizations), a couple of which could potentially go public in the near future, Ingo Bank, SVP and CFO of Parexel, said Wednesday at the Baird 2014 Healthcare Conference.
India is suddenly a safer place to research and manufacture
pharmaceuticals, thanks to legal reform, raised manufacturing
standards and reduced bureaucracy. But risk still lurks in the
loopholes and protectionism.
Degussa is streamlining its organization and decreasing the number
of business units from 20 to 17, in order to compete in the global
markets and be in a better position to exploit growth
Drug delivery specialists, Inyx has announced the acquisition of
Celltech Manufacturing Services from biopharmaceutical company UCB
for €27.5 million (€22.3 million). The acquisition adds to Inyx's
recently established operating...
Drug development company Jerini has transferred its peptide
technologies business unit to a wholly owned subsidiary which will
continue to provide and develop peptide-based services and products
for biomedical research.
SC Biosciences is to be the exclusive distributor of sensitive
tools for drug discovery with the announcement this week that it
will distribute in vivo imaging technology in Japan for US company